MyMyelomaTeam

It sounds like you're referring to Elrexfio (Elranatamab-Bcmm), which is indeed a type of treatment for multiple myeloma. Elrexfio is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy. It's designed to treat adults with relapsed or refractory multiple myeloma who have received at least four Show Full Answer

It sounds like you're referring to Elrexfio (Elranatamab-Bcmm), which is indeed a type of treatment for multiple myeloma. Elrexfio is a B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody immunotherapy. It's designed to treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. This includes treatments with a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Elrexfio works by binding to BCMA on myeloma cells and to CD3 on T cells, bringing these cells together and stimulating the T cells to eliminate the myeloma cells effectively. It's administered as a subcutaneous injection. If your doctor is considering this based on your bone biopsy results, it could be a viable option depending on your specific treatment history and current condition.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Elrexfio (Elranatamab-Bcmm) for Myeloma | MyMyelomaTeam

Bispecific T-Cell Engagers for RRMM: 6 Facts About a New Type of Treatment | MyMyelomaTeam